drugset / Trial / NCT06594679
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)
Phase 1/2
Recruiting
73 enrolled
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Eli Lilly and Company · collabGlaxoSmithKline · collab
NaSingle-groupOpen-labelOther
Summary
This is an interventional trial. The goal of this clinical trial is dose finding. There are two phases: phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with advanced ovarian cancer. Target population will be patients (woman, age \> 18 years) with epithelial ovarian, fallopian tube or peritoneal cancer treated with at least 2 lines of therapy.
Timeline
- Start
- 2024-09-26
- Primary completion
- 2027-03-20
- Completion
- 2027-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | — |
| Subject | Niraparib | Small molecule | — | — |